Navigation Links
Diabetes makes it hard for blood vessels to relax
Date:1/31/2008

One way diabetes is bad for your blood vessels is by creating too much competition for an amino acid that helps blood vessels relax, researchers say.

That amino acid, L-arginine, is broken down by the enzyme arginase to urea, which helps the body eliminate toxins resulting from the proteins we eat. Diabetics have a lot of arginase activity, which means they use a lot more L-arginine, says Dr. Maritza Romero, postdoctoral fellow at the Medical College of Georgia and lead author of the paper published in the current issue of Circulation Research.

It also means too little L-arginine is available to help nitric oxide synthase make nitric oxide, the powerful vasodilator that helps blood vessels relax, says Dr. Romero, who works in the lab of Dr. R. William Caldwell, chair of the MCG Department of Pharmacology and Toxicology and the studys corresponding author.

Researchers also found the amino acid, L-citrulline, as well as statins, compounds known to lower cholesterol, prevent elevation of arginase activity, restoring normal dilation abilities in animal models of type 1 diabetes. In fact, L-citrulline can be recycled into L-arginine.

Now they want to know specific factors and pathways involved in arginase activation and develop pharmaceutical agents to combat excessive arginase activity in diabetes. They also suggest clinical trials of L-citrulline as a supplemental therapy for diabetics with vascular problems.

Their findings also help explain why L-arginine supplement, marketed to treat hypertension, chest pain, heart failure and more, may not work long term. In the January 4, 2006 issue of the Journal of the American Medical Association, Johns Hopkins researchers reported that a clinical trial of patients taking an L-arginine supplement following a heart attack didnt improve in their vascular tone or their hearts ability to pump. In fact, more patients died who were taking L-arginine than placebo and the study was closed with the recommendation the supplement not be used by heart attack patients. The supplement still is widely marketed.

The findings of increased arginase I activity in diabetes may limit other therapeutic approaches proposed for early endothelial dysfunction such as oral L-arginine supplementation, Drs. Thomas L. Luscher and Jan Steffel, of the University of Zurich Cardiovascular Research Institute write in an accompanying editorial. Although dietary L-arginine supplementation has been shown to exert vascular protective effects in certain clinical settings, this approach is unlikely to be effective in diabetes, if the results of this study can be confirmed by patients in vivo. In fact, the findings of Romera et al may provide a possible explanation for the unexpected neutral or even adverse effects of oral L-arginine in some clinical studies, in particular patients with coronary artery disease and infarction.

A short intravenous course of L-arginine may provide short-term improvement in blood vessel tone, Dr. Romero notes. However most of L-arginine ingested goes directly to the liver to be broken down, not the bloodstream where it can promote relaxation of blood vessels, Dr. Romero says.

Arginase also is associated with vascular problems related to aging, hypertension, sickle cell disease, atherosclerosis and erectile dysfunction, Dr. Romero says. L-citrulline already is taken by some sickle cell patients to reduce breath-taking fibrosis in their lungs. In addition to helping the body turn toxins into urea that can be safely eliminated from the body, arginase also helps in collagen formation and cell proliferation, but too much can be bad. In fact, Drs. Caldwell and Romero are pursuing studies of how increased arginase activity may harden blood vessel walls.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Gender, coupled with diabetes, affects vascular disease development
3. Breakthrough research identifies how cells from pigs may cure diabetes
4. Botched production of insulin molecule may lead to diabetes
5. Joslin researchers uncover potential role of leptin in diabetes
6. Insulins brain impact links drugs and diabetes
7. Exercise improves thinking, reduces diabetes risk in overweight children
8. UVa Health System team uncovers genes role in type 1 diabetes
9. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
10. JDRF awards University of Copenhagen professor with grant to conduct innovative diabetes research
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... Georgia (PRWEB) , ... December 05, 2016 , ... ... lignin-coated nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition claims ... There are also claims directed to combination with polymers, carbon fibers, graphene, ...
(Date:12/5/2016)... 5, 2016  Renova™ Therapeutics, a biotechnology company ... and other chronic diseases, announced that Catherine ... Chief Financial Officer (CFO), effective today. ... of experience in financial management for a variety ... companies. Most recently, Ms. Bovenizer was the Vice ...
(Date:12/5/2016)... NEW YORK , December 5, 2016 ... Biotech player worldwide, with almost $108 billion of revenue ... around $170 billion were spent on global biopharmaceuticals, and ... 2017. This morning, Stock-Callers.com has lined up these four ... NWBO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... soon resume cervical and lumbar disc production, company President, Jake Lubinski will be ... are implanting the AxioMed disc in Bern, Lucerne, and Zurich to discuss the ...
Breaking Biology Technology: